<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457260</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15020481</org_study_id>
    <nct_id>NCT02457260</nct_id>
  </id_info>
  <brief_title>Oral Nitrite for Older Heart Failure Patients</brief_title>
  <acronym>ONTx+HF</acronym>
  <official_title>Study of the Utility of Oral Nitrite Therapy to Improve Skeletal Muscle Bioenergetics and Physical Capacity in Older Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gladwin, Mark, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have demonstrated nitrite therapy increases adenosine triphosphate (ATP) synthesis in
      skeletal muscle mitochondria concomitant with reduced whole-body oxygen cost during steady
      state exercise. Our own work has demonstrated safety and efficacy of an FDA investigational
      new drug (IND) approved sodium nitrite (10 milligram [mg]) capsule, and its utility to
      upregulate the sirtuin 3 adenosine monophosphate protein kinase (SIRT3-AMP) pathway of
      skeletal muscle of younger heart failure (HF) patients. It now seems exceptionally logical
      and opportune to apply these insights to older HF patients and to delineate mechanisms of
      disease and aging that respond to nitrite therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is epidemic with aging and prevalence of HF is steadily increasing as the
      population of older adults expands. Despite the fact that age always stands out as a leading
      risk factor for HF incidence as well as for poor HF prognosis, few HF trials focus
      specifically on aging physiology as a key determinant of the disease, and/or on the utility
      of targeting mechanisms associated with aging as beneficial therapeutic targets.
      Consistently, HF trials have tended to focus primarily on central mechanisms of cardiac
      pumping dysfunction despite the fact that HF-outcomes are strongly related to functional
      decrements that are largely mediated by peripheral manifestations of the disease, and which
      are particularly interrelated with aging physiology. HF-related skeletal muscle myopathy is a
      manifestation of HF that diminishes physical function, and which is likely exacerbated by
      sarcopenia, vascular stiffening, and other aspects of aging such that exercise intolerance is
      disproportionate among older HF populations as well as its insidious clinical implications.
      In a pilot investigation, the investigators will study older (age ≥70 years) adults,
      including patients with HF with reduced ejection fraction (HFrEF) and HF with preserved
      ejection fraction (HFpEF) and age-matched healthy controls, to study benefits of nitrite
      therapy (in addition to established standards of HF care) to improve physical function. In
      this pilot analysis the investigators will focus on the utility of daily nitrite supplements
      to moderate aerobic (maximal and submaximal) and strength (maximal, endurance, and power)
      indices as well as underlying skeletal muscle mechanisms (skeletal muscle mitochondrial
      performance, gene expression, and capillarity).

      Atrophy of type 1 skeletal muscle myocytes is associated with HFrEF and HFpEF. Multiple
      studies of normal aging have also demonstrated typical atrophy of type 2 skeletal muscle
      fibers. Consistently, older adults are compromised by cumulative atrophy risks, with studies
      showing losses of lean body mass as well as intrinsic skeletal muscle weakening, increased
      interstitial fat, and increased inflammation, with associated functional decrements and
      fatigue. While aerobic and strength exercise training may be used to modify such HF-related
      muscle patterns, deconditioning remains pervasive among older HF patients, and efforts to
      promote exercise interventions are typically confounded by comorbidity (e.g. arthritis,
      peripheral arterial disease, diabetes, depression), geriatric syndromes (e.g., falls,
      frailty, incontinence, dementia, poor sleep, malnutrition, auditory and vision impairments),
      as well as pain, anxiety, and logistic limitations. Even major exercise-training trials that
      provided strong reinforcements to ensure requisite behavioral changes yielded only poor
      exercise adherence. There is high conceptual rationale for a therapy that intrinsically
      improves skeletal muscle performance in HF as a vital means to improve physical function and
      moderate effects of disease itself as well as to frailties and enfeeblement associated with
      the disease. This will potentially improve efficacy and quality of care, and also potentially
      mitigate the skyrocketing costs associated with aggregate HF management.

      Studies have demonstrated nitrate therapy increases adenosine triphospate (ATP) synthesis in
      skeletal muscle mitochondria concomitant with reduced whole-body oxygen cost during steady
      state exercise. Our own work has demonstrated safety and efficacy of an FDA-IND approved
      sodium nitrite (10 mg) capsule, and its utility to upregulate the SIRT3-AMP pathway of
      skeletal muscle of younger HF patients. It now seems exceptionally logical and opportune to
      apply these insights to older HF patients and to delineate mechanisms of disease and aging
      that respond to nitrite therapy.

      Overall aims:

        1. To demonstrate that oral nitrite pills provide skeletal muscle physiological benefit in
           old HFrEF and HFpEF patients:

             -  To show that oral supplements are manifest as increased plasma nitrite.

             -  To show that increased plasma nitrite is associated with improved skeletal muscle
                (mitochondrial respirometry) and platelet (Seahorse XF) metabolism.

             -  To demonstrate that improved metabolism is associated with shifts in skeletal
                muscle anabolic gene expression (Fibronectin type III domain-containing protein 5
                [FNDC5], peroxisome proliferator-activated receptor-γ coactivator [PGC1α], Sirtuin
                3) as well as reduced catabolic gene expression (ubiquitin, muscle RING-Finger
                Protein [MuRF], Atrogin1]) and inflammation (Tumor necrosis factor alpha [TNFα],
                Interleukin 1beta (IL-1β), Interleukin six (IL-6).

        2. To demonstrate that improved skeletal physiology achieved using oral nitrate pills is
           associated with improved clinical indices in old HFrEF and HFpEF patients:

             -  To show that oral nitrite supplements increase efficiency of work, i.e., reduced
                oxygen uptake (VO2) required for the same work intensity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 8, 2016</start_date>
  <completion_date type="Actual">March 6, 2017</completion_date>
  <primary_completion_date type="Actual">March 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy Controls vs Heart Failure with reduced Ejection Fraction (HFrEF) vs Heart Failure with preserved Ejection Fraction (HFpEF) on four weeks of nitrite treatment tid.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR)</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Polymerase chain reaction (PCR) to assess pertinent gene expression within the pathways of ubiquitin [muscle ring finger protein 1 (MuRF), Atrogin1, Forkhead Box 03 (FoxO)], additionally Fibronectin type III domain-containing protein 5, the precursor of irisin (FNDC5), Peroxisome proliferator-activated receptor gamma co activator 1-alpha (PGC1α), and Sirtuin 3 were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal Muscle Bioenergetics - Mitochondrial Function</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Mitochondrial function was assessed using respirometry (State 3.12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serology-platelet Bioenergetics</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., including glycolytic(OLIGO) as well as basal and maximal respiratory rates and extracellular acidification rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Physical Function- Cardiopulmonary Exercise Test (CPX)</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Continuous metabolic gas collection or a cardiopulmonary exercise test occurred during a constant speed-steady state treadmill walking protocol (1.5mph at a 0% grade) for 5 minutes. During the final minute of the walking protocol oxygen consumption (VO2) was assessed to determined if the patient reached steady state VO2. Steady state VO2 was assessed by a less than 5% change in VO2 for a 30 second period of time. The 30 second average time is represented below in units of measure ml/kg/min. This is to show change in efficiency of performance of the constant speed test a decrease in VO2 from pre to post indicates greater efficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Physical Function- Gait Speed</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>4 meter gait speed assessed as part of the short performance physical battery (SPPB). This assessment evaluates how long it take a person can cover four meters at their usual walking speed from a stop when a person says go. This was completed twice to find the fastest speed was used as the variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Physical Function- Handgrip</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Handgrip is used as a measure of upper body strength. three trials on each hand were completed with the patient seated and the arm at a right angle. For the purposes of this analysis all trials were averaged together.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Physical Function- Balance</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Balance was assessed as part of the short performance physical battery (SPPB). This assessment evaluates three components of static stand (stands with their feet together), semi tandem (stand with the heal of one foot beside the toe of the other foot), Tandem (stands with one foot directly in front of the other). Each test is held for as many seconds as they can up to ten seconds. Static and semi tandem if held for 10 second counts as 1 point if not held it is 0 points, tandem stand if held for 10 second is 2 points, if held for 3 to9.99 it is 1 point, otherwise 0 points. Total points are added up for all balance tests for a composite score with the higher the score the better and maximum being 4, minimum 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment- In Heart Failure</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)- is a standard tool to assess the quality of life of the heart failure patients. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains with the higher the score (0-100) the better the health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology-Inflammatory Marker</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Inflammatory marker (C-reactive protein [CRP])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology-plasma Nitrite and Nitrate</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>plasma nitrite and plasma nitrate levels pre and post 4 week intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology-platelet Bioenergetics-1</measure>
    <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
    <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., extracellular acidification rate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14 N Sodium Nitrite</intervention_name>
    <description>oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
    <arm_group_label>HFpEF</arm_group_label>
    <arm_group_label>HFrEF</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <other_name>sodium nitrite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria HF Population

          -  New York Heart Association (NYHA) class II or III for the previous three months
             despite a minimum of 6 weeks of treatment. Echo criteria will be confirmed as part of
             the initial study assessment.

          -  Age ≥70 years

          -  HFrEF patients left ventricular ejection fraction (LVEF) ≤40%

          -  HFpEF patients LVEF&gt;40%, may include E/E' &gt;8, left atrial size&gt;40 mL/m2

          -  Optimal therapy according to American Heart Association (AHA)/American College of
             Cardiology(ACC) and Heart Failure Society of America (HFSa) HFrEF guidelines,
             including treatment with angiotensin-converting enzyme inhibitor (ACEI) and
             beta-blocker therapy (for at least 6 weeks), or have documented reason for variation,
             including medication intolerance, contraindication, patient preference, or personal
             physician's judgment.

          -  Patients using aspirin (ASA) will be eligible, but asked to hold the medication for 48
             hours prior to biopsy. This technique has previously been used with consistent safety.
             Patients will also be asked to avoid non-steroidal anti-inflammatory medications
             (NSAIDs) for 48 hours prior to the biopsy.

          -  Patients using anti-thrombin and anti-platelet therapy will plan to modify prior to
             muscle biopsies individually in coordination with the participant's primary
             cardiologist.

        Inclusion Criteria Age-Matched Control Population

          -  Age ≥70 years

          -  Absence of any type of cardiovascular disease.

          -  Absence of diabetes or other chronic disease processes

        Exclusion Criteria:

        Exclusion Criteria for All participants

          -  Allergy to lidocaine

          -  Dementia

          -  End-stage malignancy

          -  Orthopedic exercise limitation

          -  Chronic use of oral corticosteroids or other medications that affect muscle function.

          -  Chronic ethyl alcohol (ETOH) or drug dependency.

          -  Any bleeding disorder that would contraindicate biopsy such as history of clinically
             significant bleeding diathesis (e.g., Hemophilia A or B, Von Willebrand's Disease or
             congenital Factor VII deficiency).

          -  Psychiatric hospitalization within the last 3 months

        Exclusion Criteria HF Population

          -  Major cardiovascular event or procedure within the prior 6 weeks.

          -  HF secondary to significant uncorrected primary valvular disease (except mitral
             regurgitation secondary to left ventricular dysfunction). If valve replacement has
             been performed, patient may not be enrolled for 12 months after this procedure.

          -  Severe valvular heart disease

          -  Mechanical valve replacement requiring warfarin

          -  Currently taking clopidogrel for a recent stent placement and/or a complex
             atherosclerotic lesion such that holding clopidogrel creates disproportionate risk.

          -  ICD (Internal cardiodefibrillator) device with heart rate limits that prohibit
             exercise assessments. Referring physicians will be provided with an opportunity to
             reprogram devices so that patients can participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Forman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Gladwin, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Montefiore Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <results_first_submitted>March 5, 2018</results_first_submitted>
  <results_first_submitted_qc>June 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Daniel Forman, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02457260/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control</title>
          <description>12 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>HFpEF</title>
          <description>7 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>HFrEF</title>
          <description>2 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control</title>
          <description>12 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Heart Failure With Preserved Ejection Fraction (HFpEF)</title>
          <description>7 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Heart Failure With Reduced Ejection Fraction(HFrEF)</title>
          <description>2 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR)</title>
        <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Polymerase chain reaction (PCR) to assess pertinent gene expression within the pathways of ubiquitin [muscle ring finger protein 1 (MuRF), Atrogin1, Forkhead Box 03 (FoxO)], additionally Fibronectin type III domain-containing protein 5, the precursor of irisin (FNDC5), Peroxisome proliferator-activated receptor gamma co activator 1-alpha (PGC1α), and Sirtuin 3 were assessed.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>Health Control- 2 and 1 HFrEF participants have missing data for the gene analysis due to muscle samples not providing a clean reference value for inclusion of data analysis.. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR)</title>
          <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Polymerase chain reaction (PCR) to assess pertinent gene expression within the pathways of ubiquitin [muscle ring finger protein 1 (MuRF), Atrogin1, Forkhead Box 03 (FoxO)], additionally Fibronectin type III domain-containing protein 5, the precursor of irisin (FNDC5), Peroxisome proliferator-activated receptor gamma co activator 1-alpha (PGC1α), and Sirtuin 3 were assessed.</description>
          <population>Health Control- 2 and 1 HFrEF participants have missing data for the gene analysis due to muscle samples not providing a clean reference value for inclusion of data analysis.. 6 subjects withdrawn from the study.</population>
          <units>Relative Expression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCR -FNDC5 -PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.04" spread="0.45"/>
                    <measurement group_id="O2" value="11.91" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- FNDC5-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.79" spread="0.48"/>
                    <measurement group_id="O2" value="11.76" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- Sirtuin 3-PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" spread="0.23"/>
                    <measurement group_id="O2" value="9.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR-Sirtuin 3-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="0.18"/>
                    <measurement group_id="O2" value="9.07" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR-MuRF-PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.64" spread="0.25"/>
                    <measurement group_id="O2" value="11.90" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR-MuRF-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="0.21"/>
                    <measurement group_id="O2" value="11.57" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR-Atrogin1-PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.41" spread="0.13"/>
                    <measurement group_id="O2" value="13.55" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR-Atrogin1-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30" spread="0.25"/>
                    <measurement group_id="O2" value="13.12" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- FoX O-PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="0.27"/>
                    <measurement group_id="O2" value="10.95" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- FoX O-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74" spread="0.30"/>
                    <measurement group_id="O2" value="10.81" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- PGC1α-PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.03" spread="0.14"/>
                    <measurement group_id="O2" value="10.06" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCR- PGC1α-POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96" spread="0.22"/>
                    <measurement group_id="O2" value="9.70" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skeletal Muscle Bioenergetics - Mitochondrial Function</title>
        <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Mitochondrial function was assessed using respirometry (State 3.12).</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>2 Controls, 1 HFpEF and 1 HFrEF have no data for mitochondrial function due to no FCCP response or potential cytochrome c response. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Bioenergetics - Mitochondrial Function</title>
          <description>Obtained via analysis of skeletal muscle biopsy of the vastus lateralis, Mitochondrial function was assessed using respirometry (State 3.12).</description>
          <population>2 Controls, 1 HFpEF and 1 HFrEF have no data for mitochondrial function due to no FCCP response or potential cytochrome c response. 6 subjects withdrawn from the study.</population>
          <units>nmol O / sec/ mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mitochondrial function- Fiber 1 State 3.12 PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.88" spread="51.69"/>
                    <measurement group_id="O2" value="122.99" spread="46.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitochondrial function- Fiber 1 State 3.12 POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.59" spread="35.82"/>
                    <measurement group_id="O2" value="169.77" spread="69.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitochondrial function- Fiber 2 State 3.12 PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.84" spread="29.92"/>
                    <measurement group_id="O2" value="229.03" spread="82.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitochondrial function- Fiber 2 State 3.12 POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.68" spread="70.04"/>
                    <measurement group_id="O2" value="120.44" spread="26.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serology-platelet Bioenergetics</title>
        <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., including glycolytic(OLIGO) as well as basal and maximal respiratory rates and extracellular acidification rate.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serology-platelet Bioenergetics</title>
          <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., including glycolytic(OLIGO) as well as basal and maximal respiratory rates and extracellular acidification rate.</description>
          <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
          <units>pmol/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal respiratory rates-PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.77" spread="35.21"/>
                    <measurement group_id="O2" value="110.17" spread="22.89"/>
                    <measurement group_id="O3" value="148.71" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basal respiratory rates-POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.44" spread="31.05"/>
                    <measurement group_id="O2" value="120.90" spread="29.67"/>
                    <measurement group_id="O3" value="119.78" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLIGO OCR- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.38" spread="14.05"/>
                    <measurement group_id="O2" value="34.59" spread="22.80"/>
                    <measurement group_id="O3" value="29.49" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLIGO OCR- POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.28" spread="8.15"/>
                    <measurement group_id="O2" value="29.81" spread="11.30"/>
                    <measurement group_id="O3" value="11.25" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximal respiratory rates- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.08" spread="56.28"/>
                    <measurement group_id="O2" value="157.00" spread="46.64"/>
                    <measurement group_id="O3" value="188.09" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximal respiratory rates- POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.52" spread="52.83"/>
                    <measurement group_id="O2" value="144.99" spread="50.01"/>
                    <measurement group_id="O3" value="89.31" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Physical Function- Cardiopulmonary Exercise Test (CPX)</title>
        <description>Continuous metabolic gas collection or a cardiopulmonary exercise test occurred during a constant speed-steady state treadmill walking protocol (1.5mph at a 0% grade) for 5 minutes. During the final minute of the walking protocol oxygen consumption (VO2) was assessed to determined if the patient reached steady state VO2. Steady state VO2 was assessed by a less than 5% change in VO2 for a 30 second period of time. The 30 second average time is represented below in units of measure ml/kg/min. This is to show change in efficiency of performance of the constant speed test a decrease in VO2 from pre to post indicates greater efficiency.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Physical Function- Cardiopulmonary Exercise Test (CPX)</title>
          <description>Continuous metabolic gas collection or a cardiopulmonary exercise test occurred during a constant speed-steady state treadmill walking protocol (1.5mph at a 0% grade) for 5 minutes. During the final minute of the walking protocol oxygen consumption (VO2) was assessed to determined if the patient reached steady state VO2. Steady state VO2 was assessed by a less than 5% change in VO2 for a 30 second period of time. The 30 second average time is represented below in units of measure ml/kg/min. This is to show change in efficiency of performance of the constant speed test a decrease in VO2 from pre to post indicates greater efficiency.</description>
          <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="4.14"/>
                    <measurement group_id="O2" value="11.55" spread="0.66"/>
                    <measurement group_id="O3" value="10.05" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="2.76"/>
                    <measurement group_id="O2" value="11.79" spread="2.75"/>
                    <measurement group_id="O3" value="10.50" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Physical Function- Gait Speed</title>
        <description>4 meter gait speed assessed as part of the short performance physical battery (SPPB). This assessment evaluates how long it take a person can cover four meters at their usual walking speed from a stop when a person says go. This was completed twice to find the fastest speed was used as the variable.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Physical Function- Gait Speed</title>
          <description>4 meter gait speed assessed as part of the short performance physical battery (SPPB). This assessment evaluates how long it take a person can cover four meters at their usual walking speed from a stop when a person says go. This was completed twice to find the fastest speed was used as the variable.</description>
          <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gait Speed- Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="0.78"/>
                    <measurement group_id="O2" value="5.6" spread="2.24"/>
                    <measurement group_id="O3" value="4.22" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait Speed- Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="0.74"/>
                    <measurement group_id="O2" value="5.36" spread="1.81"/>
                    <measurement group_id="O3" value="4.06" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Physical Function- Handgrip</title>
        <description>Handgrip is used as a measure of upper body strength. three trials on each hand were completed with the patient seated and the arm at a right angle. For the purposes of this analysis all trials were averaged together.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Physical Function- Handgrip</title>
          <description>Handgrip is used as a measure of upper body strength. three trials on each hand were completed with the patient seated and the arm at a right angle. For the purposes of this analysis all trials were averaged together.</description>
          <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Handgrip- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.53" spread="7.69"/>
                    <measurement group_id="O2" value="27.02" spread="5.15"/>
                    <measurement group_id="O3" value="25.25" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Handgrip-POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="8.61"/>
                    <measurement group_id="O2" value="26.02" spread="4.23"/>
                    <measurement group_id="O3" value="25.41" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Physical Function- Balance</title>
        <description>Balance was assessed as part of the short performance physical battery (SPPB). This assessment evaluates three components of static stand (stands with their feet together), semi tandem (stand with the heal of one foot beside the toe of the other foot), Tandem (stands with one foot directly in front of the other). Each test is held for as many seconds as they can up to ten seconds. Static and semi tandem if held for 10 second counts as 1 point if not held it is 0 points, tandem stand if held for 10 second is 2 points, if held for 3 to9.99 it is 1 point, otherwise 0 points. Total points are added up for all balance tests for a composite score with the higher the score the better and maximum being 4, minimum 0.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Physical Function- Balance</title>
          <description>Balance was assessed as part of the short performance physical battery (SPPB). This assessment evaluates three components of static stand (stands with their feet together), semi tandem (stand with the heal of one foot beside the toe of the other foot), Tandem (stands with one foot directly in front of the other). Each test is held for as many seconds as they can up to ten seconds. Static and semi tandem if held for 10 second counts as 1 point if not held it is 0 points, tandem stand if held for 10 second is 2 points, if held for 3 to9.99 it is 1 point, otherwise 0 points. Total points are added up for all balance tests for a composite score with the higher the score the better and maximum being 4, minimum 0.</description>
          <population>All patients that have both pre and post data were assessed for all three groups. 6 subjects withdrawn from the study.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPPB (Balance) - PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.71"/>
                    <measurement group_id="O2" value="3.25" spread="1.5"/>
                    <measurement group_id="O3" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPPB (Balance)-POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.52"/>
                    <measurement group_id="O2" value="3.75" spread="0.5"/>
                    <measurement group_id="O3" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessment- In Heart Failure</title>
        <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)- is a standard tool to assess the quality of life of the heart failure patients. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains with the higher the score (0-100) the better the health status.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>Kansas City Cardiomyopathy Questionnaire (KCCQ)- is a standard tool to assess the quality of life of the heart failure patients. Control patients were not assessed via KCCQ given it is not a valid tool for healthy. All HF patients that completed pre and post assessment were analyzed. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>0 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessment- In Heart Failure</title>
          <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)- is a standard tool to assess the quality of life of the heart failure patients. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains with the higher the score (0-100) the better the health status.</description>
          <population>Kansas City Cardiomyopathy Questionnaire (KCCQ)- is a standard tool to assess the quality of life of the heart failure patients. Control patients were not assessed via KCCQ given it is not a valid tool for healthy. All HF patients that completed pre and post assessment were analyzed. 6 subjects withdrawn from the study.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KCCQ- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="83.40" spread="13.54"/>
                    <measurement group_id="O3" value="94.79" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ-POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="86.13" spread="18.04"/>
                    <measurement group_id="O3" value="84.90" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serology-Inflammatory Marker</title>
        <description>Inflammatory marker (C-reactive protein [CRP])</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serology-Inflammatory Marker</title>
          <description>Inflammatory marker (C-reactive protein [CRP])</description>
          <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP-PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.4"/>
                    <measurement group_id="O2" value="0.58" spread="0.52"/>
                    <measurement group_id="O3" value="27.57" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP-POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.91"/>
                    <measurement group_id="O2" value="1.26" spread="1.14"/>
                    <measurement group_id="O3" value="5.43" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serology-plasma Nitrite and Nitrate</title>
        <description>plasma nitrite and plasma nitrate levels pre and post 4 week intervention</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>On analysis of data for this report it was found that three control samples had been missed on initial running of nitrate/nitrite bring the N=7 for that assessment. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serology-plasma Nitrite and Nitrate</title>
          <description>plasma nitrite and plasma nitrate levels pre and post 4 week intervention</description>
          <population>On analysis of data for this report it was found that three control samples had been missed on initial running of nitrate/nitrite bring the N=7 for that assessment. 6 subjects withdrawn from the study.</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Nitrite- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="2.96"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                    <measurement group_id="O3" value="0.04" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Nitrite- POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.33"/>
                    <measurement group_id="O2" value="0.35" spread="0.15"/>
                    <measurement group_id="O3" value="0.11" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Nitrate- PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.01" spread="15.64"/>
                    <measurement group_id="O2" value="34.91" spread="10.44"/>
                    <measurement group_id="O3" value="39.81" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Nitrate- POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.30" spread="15.64"/>
                    <measurement group_id="O2" value="44.2" spread="5.97"/>
                    <measurement group_id="O3" value="67.68" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serology-platelet Bioenergetics-1</title>
        <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., extracellular acidification rate.</description>
        <time_frame>Baseline; PRE and 4 weeks; POST</time_frame>
        <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>4 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>HFrEF</title>
            <description>1 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serology-platelet Bioenergetics-1</title>
          <description>Platelet bioenergetics (using Seahorse XF analysis), i.e., extracellular acidification rate.</description>
          <population>Patients that completed pre post testing in each of the three arms were include in analysis. 6 subjects withdrawn from the study.</population>
          <units>mpH/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>extracellular acidification rate -PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="3.06"/>
                    <measurement group_id="O2" value="3.22" spread="3.02"/>
                    <measurement group_id="O3" value="7.34" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>extracellular acidification rate -POST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="2.61"/>
                    <measurement group_id="O2" value="3.96" spread="3.68"/>
                    <measurement group_id="O3" value="0.66" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>patients were assessed over 4 weeks of the nitrite intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control</title>
          <description>12 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>HFpEF</title>
          <description>7 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>HFrEF</title>
          <description>2 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
14 N Sodium Nitrite: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>increased heart rate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Change in blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diastolic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Belly Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tension in Head</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cramp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Twinge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>dizzy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Itchy Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Increase in poor coordination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaise With Flu</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee Strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>leg twinge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lumbrosacral strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle tightness- upper leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>back pain resolved</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>leg cramps resolved</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Shin spasm pain recurring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Impaired Depth Perception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>syncopal episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scaly itchy patch on thigh</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel E. Forman - Chief of a section of Geriatrics Cardiology</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-864-2507</phone>
      <email>formand@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

